Telo Genomics Presents New Performance Data for Its Smoldering Myeloma Prognostic Test
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) has presented new performance data for its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients at the International Myeloma Society (IMS) 2024 annual meeting. The test outperformed the current 20-2-20 scoring model in identifying both high-risk and low-risk patients in a cohort of 160 SMM patients.
Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic and Chair of the NCCN Myeloma Committee, presented the results. The TeloViewSMM test addresses a critical unmet need in SMM patient management, stratifying patients between high-risk and low-risk progression to full-stage multiple myeloma. This non-invasive liquid biopsy test can be performed using a simple blood draw and used periodically.
The company estimates the total addressable market for TeloViewSMM could result in over 500,000 tests per year, based on recent demographic studies showing SMM prevalence in approximately 0.5% of the population over 40 years old.
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ha presentato nuovi dati di performance per il suo test prognostico TeloViewSMM per pazienti affetti da mieloma multiplo smoldering (SMM) durante il congresso annuale della International Myeloma Society (IMS) 2024. Il test ha superato l'attuale modello di punteggio 20-2-20 nell'identificazione sia dei pazienti ad alto rischio che di quelli a basso rischio in un cohort di 160 pazienti con SMM.
Il Dr. Shaji Kumar, Professore di Medicina presso la Mayo Clinic e Presidente del Comitato Myeloma NCCN, ha presentato i risultati. Il test TeloViewSMM affronta un'importante esigenza insoddisfatta nella gestione dei pazienti SMM, stratificando i pazienti tra alto rischio e basso rischio di progressione verso il mieloma multiplo a pieno stadio. Questo test di biopsia liquida non invasivo può essere eseguito con un semplice prelievo di sangue e utilizzato periodicamente.
La società stima che il mercato totale per TeloViewSMM potrebbe risultare in oltre 500.000 test all'anno, basato su recenti studi demografici che mostrano una prevalenza di SMM in circa lo 0,5% della popolazione sopra i 40 anni.
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ha presentado nuevos datos de rendimiento para su prueba pronóstica TeloViewSMM para pacientes con mieloma múltiple en estado smoldering (SMM) en la reunión anual de la International Myeloma Society (IMS) 2024. La prueba superó el actual modelo de puntuación 20-2-20 para identificar tanto a pacientes de alto riesgo como de bajo riesgo en una cohorte de 160 pacientes con SMM.
El Dr. Shaji Kumar, Profesor de Medicina en Mayo Clinic y Presidente del Comité de Mieloma de la NCCN, presentó los resultados. La prueba TeloViewSMM aborda una necesidad crítica no satisfecha en la gestión de pacientes SMM, estratificando a los pacientes entre alto riesgo y bajo riesgo de progresión a mieloma múltiple a pleno estadio. Esta prueba de biopsia líquida no invasiva se puede realizar con un simple análisis de sangre y utilizar periódicamente.
La empresa estima que el mercado total direccionable para TeloViewSMM podría resultar en más de 500,000 pruebas por año, basándose en estudios demográficos recientes que muestran una prevalencia de SMM en aproximadamente el 0.5% de la población mayor de 40 años.
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF)는 2024년 국제 다발골수종 학회(IMS) 연례 회의에서, 연소형 다발골수종(SMM) 환자를 위한 TeloViewSMM 예측 테스트의 새로운 성과 데이터를 발표했습니다. 이 테스트는 현재의 20-2-20 점수 모델을 능가했습니다 160명의 SMM 환자 집단에서 고위험군과 저위험군 환자를 식별하는 데 성공했습니다.
Mayo Clinic의 의학 교수이자 NCCN 다발골수종 위원회 의장인 Dr. Shaji Kumar가 결과를 발표했습니다. TeloViewSMM 테스트는 SMM 환자 관리에서 중요한 충족되지 않은 필요를 해결하며, 환자를 고위험군과 저위험군으로 구분하여 전체 단계의 다발골수종으로의 진행 가능성을 평가합니다. 이 비침습적 액체 생검 테스트는 간단한 혈액 채취로 수행할 수 있으며 정기적으로 사용될 수 있습니다.
회사는 TeloViewSMM의 총 시장 가능성이 연간 500,000건 이상의 테스트로 이어질 수 있을 것으로 추정하며, 이는 40세 이상의 인구에서 SMM 유병률이 약 0.5%라는 최근 인구학적 연구에 기반하고 있습니다.
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) a présenté de nouvelles données de performance pour son test pronostique TeloViewSMM destiné aux patients atteints de myélome multiple à l'état smoldering (SMM) lors de la réunion annuelle de la Société Internationale du Myélome (IMS) 2024. Le test a surpassé le modèle de score actuel 20-2-20 en identifiant à la fois les patients à haut risque et à bas risque dans une cohorte de 160 patients SMM.
Le Dr Shaji Kumar, professeur de médecine à la Mayo Clinic et président du Comité Myélome de la NCCN, a présenté les résultats. Le test TeloViewSMM répond à un besoin critique non satisfait dans la gestion des patients SMM, stratifiant les patients entre haut risque et bas risque de progression vers le myélome multiple à plein stade. Ce test de biopsie liquide non invasif peut être réalisé par un simple prélèvement sanguin et utilisé périodiquement.
L'entreprise estime que le marché total adressable pour TeloViewSMM pourrait se traduire par plus de 500 000 tests par an, basé sur des études démographiques récentes montrant une prévalence de SMM chez environ 0,5 % de la population de plus de 40 ans.
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) hat auf dem jährlichen Treffen der International Myeloma Society (IMS) 2024 neue Leistungsdaten für seinen prognostischen Test TeloViewSMM für Patienten mit schwelendem multiplem Myelom (SMM) vorgestellt. Der Test übertraf das aktuelle 20-2-20-Bewertungsmodell bei der Identifizierung von Hochrisiko- und Niedrigrisikopatienten in einer Kohorte von 160 SMM-Patienten.
Dr. Shaji Kumar, Professor für Medizin an der Mayo Clinic und Vorsitzender des NCCN Myelom-Ausschusses, präsentierte die Ergebnisse. Der TeloViewSMM-Test adressiert einen kritischen unerfüllten Bedarf im Management von SMM-Patienten und stratifiziert Patienten zwischen Hochrisiko und Niedrigrisiko in Bezug auf die Progression zu vollblütigem multiplem Myelom. Dieser nicht-invasive Flüssigbiopsietest kann einfach durch eine Blutentnahme durchgeführt und regelmäßig angewendet werden.
Das Unternehmen schätzt, dass der insgesamt adressierbare Markt für TeloViewSMM in über 500.000 Tests pro Jahr resultieren könnte, basierend auf aktuellen demografischen Studien, die zeigen, dass die Prävalenz von SMM bei etwa 0,5% der Bevölkerung über 40 Jahren liegt.
- TeloViewSMM test outperformed the current 20-2-20 scoring model in identifying high-risk and low-risk SMM patients
- Non-invasive liquid biopsy test can be performed using a simple blood draw
- Estimated addressable market of over 500,000 tests per year
- Addresses a critical unmet need in SMM patient management
- Potential to offer a paradigm shift in SMM patient treatment
- None.
Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has presented the most recent performance results of its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients at the recent International Myeloma Society (IMS) 2024 annual meeting 2024 in Brazil.
The new data was based on a comparative analysis between TeloViewSMM's results and the 20-2-20 scoring model, which is currently included in the smoldering myeloma prognostic international guidelines. The TeloViewSMM prognostic test outperformed the 20-2-20 score in identifying both true positive (high risk patients) and true negative (low risk patients). The analysis was conducted on the same cohort of 160 SMM patients. The presented results supersede the performance of all historic attempts to stratify SMM patients to their respective risk of progression to full stage multiple myeloma and presents a viable prognostic product with high sensitivity and specificity to stratify the SMM patients.
The results of this analysis were presented in an important discussion session in the IMS 2024 program by Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic and Chair of the National Comprehensive Cancer Network (NCCN) Myeloma Committee, and Telo's collaborator and Lead Clinical Investigator on the TeloViewSMM validation studies.
The TeloViewSMM test is for SMM, a precursor to multiple myeloma. The test stratifies patients flagged with the elevated M-protein biomarker, between patients that are high-risk to progress to the full stage of the myeloma disease, and those that are low-risk patients, and confirms the stability of disease in these patients. To date, this has been a critical unmet need in the management of SMM patients.
High risk SMM patients may benefit from immediate treatment intervention, with a possibility to achieve cure due to recent advancement in treatment regimens. Alternatively, low risk patients can be monitored using TeloViewSMM, without exposing these patients to unnecessary and debilitating treatment. Critically, TeloViewSMM can be used periodically as a non-invasive liquid biopsy test that can be performed using a simple blood draw.
Recent demographic studies have shown that SMM prevalence provides a significant market opportunity with an estimated
"We are excited to present, what we believe to be, industry leading results of our smoldering myeloma test. Stratifying smoldering patients has long been understood to be an important unmet need in effectively managing the disease of these patients," said Sherif Louis, Telo's President and CTO. "Smoldering myeloma patient management was a high-profile topic in the IMS annual meeting garnering a significant level of interest. We were pleased with the feedback as TeloViewSMM has the potential to offer a paradigm shift in the treatment of these patients, that may lead to improved clinical outcomes and quality of life."
About TELO
Telo Genomics Corp. is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TELO-MM is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Sherif Louis,
President & CTO
Telo Genomics
416-673-8487
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView® platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227376
FAQ
What is the performance of Telo Genomics' TeloViewSMM test for smoldering multiple myeloma?
How is the TeloViewSMM test performed for TDSGF stock's smoldering myeloma patients?
What is the estimated market size for Telo Genomics' (TDSGF) TeloViewSMM test?
Who presented the TeloViewSMM test results for TDSGF at the IMS 2024 annual meeting?
